新井正法先生の論文が、Diabetes care.に発表されました。
Arai M, Shirakawa J, Konishi H, Sagawa N, Terauchi Y. Bullous Pemphigoid and Dipeptidyl Peptidase 4 Inhibitors: A Disproportionality Analysis Based on the Japanese Adverse Drug Event Report Database. Diabetes Care. in press, 2018. PubMed
Impact factor (2017): 13.397
木村雅代先生の論文が、J Clin Med Res.に発表されました。
Kimura M, Kondo Y, Aoki K, Shirakawa J, Kamiyama H, Kamiko K, Nakajima S, Terauchi Y. A Randomized Controlled Trial of a Mini Low-Carbohydrate Diet and an Energy-Controlled Diet Among Japanese Patients with Type 2 Diabetes. J Clin Med Res. 10(3):182-188, 2018. PubMed
井上英明先生の論文が、J Biol Chem.に発表されました。
Inoue H, Shirakawa J, Togashi Y, Tajima K, Okuyama T, Kyohara M, Tanaka Y, Orime K, Saisho Y, Yamada T, Shibue K, Kulkarni RN, Terauchi Y. Signaling between pancreatic β-cells and macrophages via S100 calcium-binding protein A8 exacerbates β-cell apoptosis and islet inflammation. J Biol Chem. 293(16):5934-5946, 2018. PubMed
白川純先生の論文が、Ann Transl Med. に発表されました。
Shirakawa J, Terauchi Y. SUSTAINable management of type 2 diabetes: feasibility of use and safety of semaglutide. Ann Transl Med. 6(7):129, 2018. PubMed
寺内康夫先生の論文が、Diabetes Obes Metab.、J Diabetes Investig.、Diabetes Obes Metab.に発表されました。
Terauchi Y, Riddle MC, Hirose T, Koyama M, Cheng X, Takahashi Y, Bolli GB. Glycaemic control, hypoglycaemia, and weight change with insulin glargine 300 U/mL versus insulin glargine 100 U/mL in Japanese adults with type 2 diabetes: a 12-month comparison by concomitant sulphonylurea and/or glinide use. Diabetes Obes Metab. 2018 Jun 11. doi: 10.1111/dom.13414. [Epub ahead of print] PubMed
Terauchi Y, Yamada Y, Watada H, Nakatsuka Y, Shiosakai K, Washio T, Taguchi T. Efficacy and safety of the G protein-coupled receptor 119 agonist DS-8500a in Japanese type 2 diabetes mellitus patients with inadequate glycemic control on sitagliptin: A phase 2 randomized placebo-controlled study. J Diabetes Investig. 2018 Apr 1. doi: 10.1111/jdi.12846. [Epub ahead of print] PubMed
Terauchi Y, Tamura M, Senda M, Gunji R, Kaku K. Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS). Diabetes Obes Metab. 2018 May;20(5):1176-1185. doi: 10.1111/dom.13213. Epub 2018 Feb 11. PubMed